// App-Quantinova.ai

2507 : Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met antibody, in patients (pts) with advanced solid tumors.

Researchers

Presenter

  • John H. Strickler

Principal Investigators

  • Patricia Lo Russo

  • Chia-Jui Yen

  • Patrick Kaminker

  • Peter Ansell

  • Anahita Bhathena

  • Shekman Wong

  • Matthew W. Dudley

  • Louie Naumovski

  • Ramesh K. Ramanathan

  • Chia-Chi Lin

  • Yoon-Koo Kang

Medical Centers

  • AbbVie Biotherapeutics, Redwood City, CA

  • Karmanos Cancer Institute, Wayne State University, Detroit, MIDuke University Medical Center, Durham, NCVirginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ

  • AbbVie, Inc., North Chicago, IL

  • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

  • National Cheng Kung University Hospital, Tainan City, Taiwan

Locations

  • United States

  • Taiwan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • ABT-700

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01472016

Sponsors

  • Abbvie

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved